Compare Inovio Pharmaceuticals Inc (INO) vs Intuitive Surgical, Inc. (ISRG) Price & Performance

Inovio Pharmaceuticals IncTrade

Intuitive Surgical, Inc.Trade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Intuitive Surgical, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M), while Intuitive Surgical, Inc. trades at $401.27 (market cap $141.75B). The key difference: Intuitive Surgical, Inc. is far larger — about 1804.6× Inovio Pharmaceuticals Inc's market cap, and Intuitive Surgical, Inc. is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

	INO	ISRG
Market Cap	$78.55M	$141.75B
Sector	Health	Health
52-Week High	$2.87	$592.85
52-Week Low	$0.66	$332.02
Enterprise Value	$49.56M	$136.53B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Intuitive Surgical, Inc.

Intuitive Surgical (ISRG) trades at $401.46, up 2.05% today, with strong quarterly earnings beats and bullish analyst consensus. The stock shows robust revenue growth, expanding margins, and solid cash flow, supported by the da Vinci 5 system adoption. Technical indicators are mixed, with RSI signaling overbought conditions but moving averages bullish.

Outlook remains positive due to durable demand and innovation, though high valuation and competition pose risks. Upside to the $518.10 consensus target offers potential, but investors should weigh premium multiples against growth sustainability.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INO

FDA review of INOVIO's INO-3107 for RRP targets Oct 2026 approval; positive Phase 3 VGX-3100 results in China reported.PRNewsWire · 7 hours agoBullish View details →

ISRG

Deutsche Bank upgrades Intuitive Surgical to Buy as valuation drops amid market challengesGordon Thompson · 9 hours agoBullish Intuitive Surgical rated Hold with 9.17% upside, driven by growth in ASC procedures and limited remanufacturing risks.Seeking Alpha · 12 hours agoBullish Intuitive Surgical stock drops 30% YTD but shows strong growth and recurring revenue in surgical robotics.24/7 Wall Street · 1 day agoBullish View details →

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

About Intuitive Surgical, Inc.

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.